Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 27, Issue suppl_5, Pages v58-v68
Publisher
Oxford University Press (OUP)
Online
2017-02-04
DOI
10.1093/annonc/mdw328
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
- (2016) Nizar M. Tannir et al. EUROPEAN UROLOGY
- Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy
- (2016) Lorenzo Marconi et al. EUROPEAN UROLOGY
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
- (2016) Holger Moch et al. EUROPEAN UROLOGY
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
- (2016) Naomi B Haas et al. LANCET
- Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
- (2016) Andrew J Armstrong et al. LANCET ONCOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
- (2015) N. I. Cherny et al. ANNALS OF ONCOLOGY
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies
- (2015) Brian Rini et al. LANCET ONCOLOGY
- The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
- (2015) Jenny J Ko et al. LANCET ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
- (2014) M. H. Voss et al. CLINICAL CANCER RESEARCH
- Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2014) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Genetics of Clear-Cell Renal Cell Carcinoma
- (2014) James Brugarolas JOURNAL OF CLINICAL ONCOLOGY
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- (2014) Robert J Motzer et al. LANCET ONCOLOGY
- Local treatments for metastases of renal cell carcinoma: a systematic review
- (2014) Saeed Dabestani et al. LANCET ONCOLOGY
- Radiotherapy for renal-cell carcinoma
- (2014) Gert De Meerleer et al. LANCET ONCOLOGY
- Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
- (2014) Marco Gerlinger et al. NATURE GENETICS
- The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters
- (2013) Brett Delahunt et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
- (2013) R J Motzer et al. BRITISH JOURNAL OF CANCER
- Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
- (2013) A. A. Hakimi et al. CLINICAL CANCER RESEARCH
- Systematic Review of Adrenalectomy and Lymph Node Dissection in Locally Advanced Renal Cell Carcinoma
- (2013) Hendrika J. Bekema et al. EUROPEAN UROLOGY
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- A clear picture of renal cell carcinoma
- (2013) A Ari Hakimi et al. NATURE GENETICS
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic Review of Oncological Outcomes Following Surgical Management of Localised Renal Cancer
- (2012) Steven MacLennan et al. EUROPEAN UROLOGY
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
- (2011) Maxine Sun et al. EUROPEAN UROLOGY
- Active Surveillance of Small Renal Masses: Progression Patterns of Early Stage Kidney Cancer
- (2011) Michael A.S. Jewett et al. EUROPEAN UROLOGY
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
- (2010) Martin Kocher et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidemiology and risk factors for kidney cancer
- (2010) Wong-Ho Chow et al. Nature Reviews Urology
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search